Biosergen recently announced the completion of treatment for the first cohort of patients in its proof-of-concept trial for its antifungal drug candidate BSG005. Most patients improved significantly, reflecting BSG005’s potential as a life-saving therapy. The next step involves dose escalation for the upcoming cohort. Importantly, between November 18 and 29, shareholders …
